Optimal blockade of the renin-angiotensin-aldosterone system

被引：13

作者：

Nussberger, Juerg ^{[1
]}

Bohlender, Juergen ^{[2
]}

机构：

[1] CHU Vaudois, Dept Internal Med, Div Angiol & Hypertens, CH-1011 Lausanne, Switzerland

[2] Hop Fribourgeois, Med Clin, CH-1708 Fribourg, Switzerland

来源：

NATURE REVIEWS CARDIOLOGY | 2013年 / 10卷 / 04期

关键词：

ALISKIREN; INHIBITION;

D O I：

10.1038/nrcardio.2013.28

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inhibition of the renin-angiotensin-aldosterone system (RAAS) is a successful therapy for hypertension, heart failure, and renal insufficiency. Overdosing of RAAS inhibitors is occasionally observed when several agents are used together, and can cause adverse events such as hypotension, hyperkalaemia, and renal failure. We advocate optimal, rather than complete, RAAS blockade. Nussberger, J. & Bohlender, J. Nat. Rev. Cardiol. 10, 183-184 (2013); published online 12 March 2013; doi:10.1038/nrcardio.2013.28

引用

页码：183 / 184

页数：2

共 50 条

[21] Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease
Siragy, Helmy M.
Carey, Robert M.
AMERICAN JOURNAL OF NEPHROLOGY, 2010, 31 (06) : 541 - 550
[22] Dynamic Changes in the Renin-Angiotensin-Aldosterone System and the Beneficial Effects of Renin-Angiotensin-Aldosterone Inhibitors on Spatial Learning and Memory in a Rat Model of Chronic Cerebral Ischemia
Huang, Xinwu
Lu, Guozhou
Li, Guochun
Li, Hua
Li, Beihua
Yin, Jiazhen
Cao, Shousong
FRONTIERS IN NEUROSCIENCE, 2017, 11
[23] Mechanisms of Impaired Potassium Handling With Dual Renin-Angiotensin-Aldosterone Blockade in Chronic Kidney Disease
Preston, Richard A.
Afshartous, David
Garg, Dyal
Medrano, Sergio
Alonso, Alberto B.
Rodriguez, Rolando
HYPERTENSION, 2009, 53 (05) : 754 - U28
[24] Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria
Morales, Enrique
Gutierrez, Eduardo
Caro, Jara
Sevillano, Angel
Rojas-Rivera, Jorge
Praga, Manuel
NEFROLOGIA, 2015, 35 (06): : 554 - 561
[25] Optimal Antagonism of the Renin-Angiotensin-Aldosterone SystemDo We Need Dual or Triple Therapy?
Christian Werner
Janine Pöss
Michael Böhm
Drugs, 2010, 70 : 1215 - 1230
[26] Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
Andersen, Karl
CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 137 - 151
[27] Paricalcitol counteracts the increased contrast induced nephropathy caused by renin-angiotensin-aldosterone system blockade therapy in a rat model
Sahin, I.
Ozkaynak, B.
Sar, M.
Biter, H. I.
Mert, B.
Okuyan, E.
Kayalar, N.
Can, M. M.
Gungor, B.
Erentug, V.
Dinckal, M. H.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (19) : 2895 - 2902
[28] The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease
Simoes e Silva, Ana Cristina
Flynn, Joseph T.
PEDIATRIC NEPHROLOGY, 2012, 27 (10) : 1835 - 1845
[29] Stroke, high blood pressure and the renin-angiotensin-aldosterone system - new developments
Atkinson, Jeffrey
FRONTIERS IN PHARMACOLOGY, 2011, 2
[30] Evolving understanding of the renin-angiotensin-aldosterone system: Pathophysiology and targets for therapeutic intervention
Gradman, Alan H.
AMERICAN HEART JOURNAL, 2009, 157 (06) : S1 - S6

← 1 2 3 4 5 →